Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT05365217
- Locations
- 🇨🇳
The Affiliated hospital of Guizhou Medical University-Hemato, Guiyang, Guizhou, China
🇨🇳Beijing Children's Hospital，Capital Medical University, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital-Hematology, Fuzhou, Fujian, China
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
- Conditions
- Healthy Volunteers (Diabetes Mellitus, Type 2)
- Interventions
- Drug: Placebo (NNC0519-0130)
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 161
- Registration Number
- NCT05363774
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇰Novo Nordisk Investigational Site, Søborg, Denmark
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1291
- Registration Number
- NCT05352815
- Locations
- 🇺🇸
Endeavor Health, Skokie, Illinois, United States
🇵🇹Unidade Local De Saude Da Regiao De Aveiro E.P.E., Aveiro, Portugal
🇳🇴St. Olavs Hospital HF, Trondheim, Norway
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II
- Conditions
- Healthy Volunteers; High Cholesterol
- Interventions
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 152
- Registration Number
- NCT05333107
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc., Los Angeles, California, United States
🇺🇸Altasciences, Cypress, California, United States
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
- Conditions
- SGA, Turner Syndrome, Noonan Syndrome, ISS
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 399
- Registration Number
- NCT05330325
- Locations
- 🇯🇵
Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics, Kyoto, Japan
🇯🇵Nara Prefecture General Medical Center, Nara-shi, Nara, Japan
🇯🇵Institute of Science Tokyo Hospital, Tokyo, Japan
Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 175
- Registration Number
- NCT05324462
- Locations
- 🇨🇴
Novo Nordisk Investigational Site, Bucaramanga, Santander, Colombia
An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4089
- Registration Number
- NCT05317845
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Abu Dhabi, United Arab Emirates
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 187
- Registration Number
- NCT05316662
- Locations
- 🇲🇽
Centro de Investigacion Clinica Endocrinologica de Jalisco, Guadalajara, Jalisco, Mexico
🇲🇽CICEJ Centro de Investigacion Clinica Endocrinologica de Jalisco SC, Guadalajara, Jalisco, Mexico
A Study Investigating the Safety and Performance of DV3395, a New Concept Device for the Delivery of Medicine.
- Conditions
- Healthy Volunteers, Medical Device
- Interventions
- Device: DV3395 C1
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 65
- Registration Number
- NCT05314283
- Locations
- 🇳🇱
ICON - location Groningen, Groningen, Netherlands
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
- Conditions
- Noonan Syndrome
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 221
- Registration Number
- NCT05308927
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, Toulouse cedex 9, France